Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...

Aspiring to become the leader in inflammasome-targeted therapeutics, Novartis will acquire IFM Tre, a subsidiary of Boston-based IFM Therapeutics, in a deal worth up to $1.6 billion. The purchase ...

Just two weeks after hauling in a $31 million series A funding round to form a new subsidiary, Boston-based IFM Therapeutics is laying out a case for the unit’s primary drug target: a signaling ...

BOCA RATON, Fla. & MELBOURNE, Australia & LAS VEGAS--(BUSINESS WIRE)--DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) and IFM Investors today announced they have completed their previously ...

In their search for new ways to treat cancer, biotech firms are learning more about the immune system than ever before. The red hot strategy of activating the immune system to treat cancer is leading ...

IFM Investors, the $148 billion funds manager, has warned the public that an email soliciting investment in a high-yield bond fund is fraudulent. In a statement posted on its website on Wednesday, ...